AngioSoma

AngioSoma, Inc. is a publicly traded, clinical stage biopharmaceutical company headquartered in Houston, Texas. The company employs a small team of three individuals and generates an annual revenue of $2.5 million. AngioSoma is dedicated to enhancing the efficacy of existing treatments, particularly those used in endovascular interventions for peripheral artery disease (PAD). AngioSoma's primary product is Liprostin™, a pharmaceutical treatment specifically designed for PAD. This innovative drug has already achieved significant milestones, successfully completing both FDA Phase I and three Phase II clinical trials. The company is actively engaged in discussions with contract research organizations to expedite the completion of its FDA-approved Phase III protocol. Upon successful completion, AngioSoma aims to submit a new drug application for Liprostin™ to gain marketing authorization in the United States and its territories. AngioSoma distinguishes itself through its commitment to improving the standard of care for PAD patients. The company's focus on developing innovative therapies and conducting rigorous clinical trials underscores its dedication to delivering effective and safe treatments. The successful progression of Liprostin™ through multiple clinical trial phases demonstrates the potential of this drug to significantly impact the lives of individuals suffering from PAD. For more information about AngioSoma, Inc. and its groundbreaking work in the field of PAD treatment, please visit their website at angiosoma.com.